Logo image of HTGM

HTG MOLECULAR DIAGNOSTICS (HTGM) Stock Fundamental Analysis

NASDAQ:HTGM - Nasdaq - US40434H3021 - Common Stock - Currency: USD

0.48  -0.12 (-20%)

After market: 0.4815 +0 (+0.31%)

Fundamental Rating

1

Taking everything into account, HTGM scores 1 out of 10 in our fundamental rating. HTGM was compared to 36 industry peers in the Health Care Technology industry. HTGM may be in some trouble as it scores bad on both profitability and health. HTGM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HTGM had negative earnings in the past year.
HTGM had a negative operating cash flow in the past year.
HTGM had negative earnings in each of the past 5 years.
In the past 5 years HTGM always reported negative operating cash flow.
HTGM Yearly Net Income VS EBIT VS OCF VS FCFHTGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M -20M -25M

1.2 Ratios

The profitability ratios for HTGM are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HTGM Yearly ROA, ROE, ROICHTGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600

1.3 Margins

The Gross Margin of HTGM (21.69%) is worse than 79.55% of its industry peers.
In the last couple of years the Gross Margin of HTGM has declined.
The Profit Margin and Operating Margin are not available for HTGM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.29%
GM growth 5Y-15.73%
HTGM Yearly Profit, Operating, Gross MarginsHTGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400

More info and screens

1

2. Health

2.1 Basic Checks

HTGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
HTGM has more shares outstanding than it did 1 year ago.
The debt/assets ratio for HTGM has been reduced compared to a year ago.
HTGM Yearly Shares OutstandingHTGM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
HTGM Yearly Total Debt VS Total AssetsHTGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

HTGM has an Altman-Z score of -35.30. This is a bad value and indicates that HTGM is not financially healthy and even has some risk of bankruptcy.
HTGM's Altman-Z score of -35.30 is on the low side compared to the rest of the industry. HTGM is outperformed by 90.91% of its industry peers.
A Debt/Equity ratio of 7.10 is on the high side and indicates that HTGM has dependencies on debt financing.
HTGM has a worse Debt to Equity ratio (7.10) than 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.1
Debt/FCF N/A
Altman-Z -35.3
ROIC/WACCN/A
WACC4.37%
HTGM Yearly LT Debt VS Equity VS FCFHTGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.40 indicates that HTGM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.40, HTGM is not doing good in the industry: 61.36% of the companies in the same industry are doing better.
A Quick Ratio of 1.30 indicates that HTGM should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.30, HTGM is not doing good in the industry: 61.36% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.3
HTGM Yearly Current Assets VS Current LiabilitesHTGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

HTGM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.99%, which is quite impressive.
HTGM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.21%.
Measured over the past years, HTGM shows a very negative growth in Revenue. The Revenue has been decreasing by -15.48% on average per year.
EPS 1Y (TTM)44.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.54%
Revenue 1Y (TTM)-28.21%
Revenue growth 3Y-30.79%
Revenue growth 5Y-15.48%
Sales Q2Q%-12.83%

3.2 Future

Based on estimates for the next years, HTGM will show a very strong growth in Earnings Per Share. The EPS will grow by 39.92% on average per year.
The Revenue is expected to grow by 53.55% on average over the next years. This is a very strong growth
EPS Next Y81.55%
EPS Next 2Y39.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.6%
Revenue Next 2Y53.55%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HTGM Yearly Revenue VS EstimatesHTGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
HTGM Yearly EPS VS EstimatesHTGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HTGM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HTGM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HTGM Price Earnings VS Forward Price EarningsHTGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HTGM Per share dataHTGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

HTGM's earnings are expected to grow with 39.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.92%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HTGM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HTG MOLECULAR DIAGNOSTICS

NASDAQ:HTGM (6/14/2023, 8:00:02 PM)

After market: 0.4815 +0 (+0.31%)

0.48

-0.12 (-20%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-10 2023-05-10/amc
Earnings (Next)08-09 2023-08-09/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners201.96%
Ins Owner Change0%
Market Cap1.06M
Analysts82.86
Price Target6.12 (1175%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-48.59%
Min EPS beat(2)-81.95%
Max EPS beat(2)-15.22%
EPS beat(4)2
Avg EPS beat(4)-14.95%
Min EPS beat(4)-81.95%
Max EPS beat(4)24.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.27%
Min Revenue beat(2)-36.73%
Max Revenue beat(2)-1.8%
Revenue beat(4)0
Avg Revenue beat(4)-34.25%
Min Revenue beat(4)-56.97%
Max Revenue beat(4)-1.8%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-40%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-162.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-67.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-28.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.17
P/FCF N/A
P/OCF N/A
P/B 2.24
P/tB 2.24
EV/EBITDA N/A
EPS(TTM)-18.15
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-7.61
FCFYN/A
OCF(TTM)-7.6
OCFYN/A
SpS2.81
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.69%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.29%
GM growth 5Y-15.73%
F-Score3
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 7.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.3
Altman-Z -35.3
F-Score3
WACC4.37%
ROIC/WACCN/A
Cap/Depr(3y)42.2%
Cap/Depr(5y)55.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.54%
EPS Next Y81.55%
EPS Next 2Y39.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-28.21%
Revenue growth 3Y-30.79%
Revenue growth 5Y-15.48%
Sales Q2Q%-12.83%
Revenue Next Year0.6%
Revenue Next 2Y53.55%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.73%
OCF growth 3YN/A
OCF growth 5YN/A